Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
But, like Merck two weeks ago, GSK has failed to hit overall survival.
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Data deteriorate, leaving cash-strapped Affimed relying on a post-hoc analysis and higher dosing.
Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
